Nasdaq Biotech Stocks: Major Stake Sale by Participating Funds

RA Capital Management, whose fund holds a board seat at Vor Biopharma Inc. (NASDAQ: VOR), disclosed that its affiliated funds sold portions of their holdings on the U.S. markets on April 2, 6 and from April 8 to 10, resulting in two successive reductions in their indirect stake. The cumulative sale totaled approximately 1.5 million shares, equivalent to roughly $25 million (about KRW 30 billion). Despite these divestitures, RA Capital stated that it still holds approximately 12.4 million shares, including warrants and options, representing 19.9% of Vor Biopharma’s outstanding stock. In an amended Schedule 13D filed on April 8, RA Capital reiterated that these transactions were merely portfolio rebalancing within a passive investment framework and that it has no activist intentions.

Meanwhile, H.C. Wainwright has lowered its price target on Vor Biopharma to $31. Over the past five months, the company has raised more than $330 million (about KRW 440 billion) through private placements and public offerings to bolster its clinical programs and financial position.

Vor Biopharma, a Nasdaq‐listed clinical‐stage biotech, is developing telitacicept, a fusion protein designed to simultaneously inhibit BAFF and APRIL for the treatment of autoimmune diseases. Boston‐based RA Capital Management specializes in healthcare and biotechnology investments, managing approximately $12.6 billion in assets with a focus on both public and private life science companies.